ATL1102 Antisense and Multiple Sclerosis, page-2

This is just from memory - the company decided to drop it or put it on the shelf due to the foreseen high costs involved in moving forward on MSC trials at that time. Instead, they seemingly out of the blue, decided to have a crack at DMD and with no explanation to shareholders chose to undertake the trial themselves here in Melbourne - the most brilliant thing the company has ever done. This happened fairly quickly after Mr. Goolsbee joined the Board. My recollection is that he said he had a particular interest in the potential for ATL11O2 for MSC at his first Board meeting, so perhaps he sees the DMD trial as one smaller step towards that ?